



Article

Antioxidative Indenone and Benzophenone Derivatives from the Mangrove-Derived Fungus *Cytospora heveae* NSHSJ-2

Ge Zou ¹, Taobo Li ¹, Wencong Yang ¹, Bing Sun ¹, Yan Chen ¹, Bo Wang ¹, Yanghui Ou ², Huijuan Yu ^{2,*} and Zhigang She ^{1,*}

- ¹ School of Chemistry, Sun Yat-Sen University, Guangzhou 510275, China
- ² Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Institute of Zoology, Guangdong Academy of Sciences, Guangzhou 510260, China
- * Correspondence: yuhj@giz.gd.cn (H.Y.); cesshzhg@mail.sysu.edu.cn (Z.S.)

Abstract: Seven new polyketides, including four indenone derivatives, cytoindenones A–C (1, 3–4), 3'-methoxycytoindenone A (2), a benzophenone derivative, cytorhizophin J (6), and a pair of tetralone enantiomers, (±)-4,6-dihydroxy-5-methoxy- α -tetralone (7), together with a known compound (5) were obtained from the endophytic fungus *Cytospora heveae* NSHSJ-2 isolated from the fresh stem of the mangrove plant *Sonneratia caseolaris*. Compound 3 represented the first natural indenone monomer substituted by two benzene moieties at C-2 and C-3. Their structures were determined by the analysis of 1D and 2D NMR, as well as mass spectroscopic data, and the absolute configurations of (±)-7 were determined on the basis of the observed specific rotation value compared with those of the tetralone derivatives previously reported. In bioactivity assays, compounds 1, 4–6 showed potent DPPH· scavenging activities, with EC50 values ranging from 9.5 to 16.6 μM, better than the positive control ascorbic acid (21.9 μM); compounds 2–3 also exhibited DPPH· scavenging activities comparable to ascorbic acid.

Keywords: mangrove endophytic fungus; *Cytospora heveae*; indenone; benzophenone; DPPH-scavenging activity

Citation: Zou, G.; Li, T.; Yang, W.; Sun, B.; Chen, Y.; Wang, B.; Ou, Y.; Yu, H.; She, Z. Antioxidative Indenone and Benzophenone Derivatives from the Mangrove-Derived Fungus *Cytospora heveae* NSHSJ-2. *Mar. Drugs* **2023**, *21*, 181. https://doi.org/10.3390/md21030181

Academic Editor: Chang-Lun Shao

Received: 23 February 2023 Revised: 13 March 2023 Accepted: 14 March 2023 Published: 14 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Indenones are characterized by a cyclopentenone ring fused with an aromatic benzene ring, providing a rigid bicyclic ring framework which enables the extensive evaluation of structure–activity relationship analysis of target therapeutic molecules [1], and indenone derivatives have been synthesized extensively for drug discovery [2–5]. The indenone moiety usually exists in natural products as a structural fragment or a small independent molecule [6–11], and 2,3-diaryl indenone analogues are rarely reported [12–14]. These compounds were considered to be dimers of benzophenone, xanthone, diphenyl ether moieties and indanone moieties, and there was no natural 2,3-diphenyl indenone monomer reported previously. Indenones have multiple bioactivities, including cytotoxicity, DPPH· scavenging activity, anti-inflammatory activity, anti-osteoporosis activity, human DNA dealkylation repair enzyme AlkBH3 inhibitory activity, and PPAR γ agonistic activity [2–5,8,13–15].

Mangrove-associated fungi are known to be an essential source of natural products for the discovery of new drug leads [16,17]. In our continuing search for structurally diverse and biologically active metabolites from mangrove endophytic fungi [18–22], a chemical investigation for new secondary metabolites from mangrove endophytic fungus *Cytospora heveae* NSHSJ-2, which was isolated from the fresh stem of the mangrove plant *Sonneratia caseolaris*, led to the isolation and characterization of seven new polyketides (Figure 1), including four new indenone derivatives, cytoindenones A–C (1, 3–4), 3′-

Mar. Drugs **2023**, 21, 181 2 of 10

methoxycytoindenone A (2), a new benzophenone derivative, cytorhizophin J (6), and a pair of undescribed tetralone enantiomers, (\pm)-4,6-dihydroxy-5-methoxy- α -tetralone (7), together with a known compound, cytosporaphenones E (5) [23]. Among them, compound 3 represented the first natural indenone monomer substituted by two benzene moieties at C-2 and C-3. Herein, the isolation, structure elucidation, and DPPH· radical scavenging activities of these compounds are described.

Figure 1. Structure of compounds 1–7.

2. Results

6'

7'

2.1. Structure Elucidation

Compound **1** was obtained as brown oil. Its molecular formula was assigned as $C_{19}H_{16}O_6$ on the basis of HRESIMS analysis at m/z 363.08383 [M + Na]⁺ (calcd. For $C_{19}H_{16}O_6Na$, 363.08391), which was determined to possess 12 degrees of unsaturation. In the 1H NMR spectrum (Table 1), the signals for five olefinic protons (δ_H 7.06, 6.79, 6.65, 6.50 and 6.50), two methylenes (δ_H 2.49 and 2.42) and one methyl (δ_H 2.24) were observed. The ^{13}C NMR data (Table 2) exhibited 19 carbon resonances, including two carbonyls (δ_C 198.2 and 174.3), two aromatic rings (A and C) (δ_C 156.2, 156.2, 151.7, 140.7, 134.3, 130.7, 127.1, 124.5, 116.4, 110.6, 108.0, 108.0), two olefinic carbons for one double bond (δ_C 152.1, 134.4), two methylenes (δ_C 32.4 and 20.4) and one methyl (δ_C 21.0).

No.	1 a	2 b	3 c	4 °
5	6.65, s	6.54, s	6.63, s	6.58, s
7	6.79, s	6.82, s	6.87, s	6.75, s
10	6.50, d (8.1)	6.57, d (8.3)	6.33, d (8.1)	6.40, d (8.2)
11	7.06, t, (8.1)	7.15, t (8.3)	6.99, t (8.1)	7.02, t (8.2)
12	6.50, d (8.1)	6.57, d (8.3)	6.33, d (8.1)	6.40, d (8.2)
14	2.24, s	2.17, s	2.27, s	2.22, s
1′	2.42, m	2.42, t (7.1)		3.41, s
2′	2.49, m	2.66, t (7.1)	7.30, m	
3′			7.15, m	7.09, m
4'		3.58, s	7.13, m	7.07, m
5′			7.15, m	7.02, t (8.2)

Table 1. ¹H NMR data of **1–4** (*J* in Hz).

7.30, m

7.07, m

7.09, m

^a Data were recorded in Actone-*d*₆ at 400 MHz for ¹H NMR. ^b Data were recorded in CDCl₃ at 400 MHz for ¹H NMR. ^c Data were recorded in CD₃OD at 600 MHz for ¹H NMR.

Mar. Drugs 2023, 21, 181 3 of 10

No.	1 a	2 ь	3 °	4 °
1	198.2, C	197.5, C	199.1, C	200.2, C
2	134.4, C	135.2, C	133.6, C	134.8, C
3	152.1, C	148.3, C	154.0, C	154.8, C
3a	127.1, C	123.7, C	127.1, C	127.4, C
4	151.7, C	150.0, C	153.1, C	152.3, C
5	124.5, CH	124.7, CH	125.1, CH	125.0, CH
6	140.7, C	141.5, C	141.9, C	141.1, C
7	116.4, CH	118.2, CH	116.9, CH	116.6, CH
7a	134.3, C	132.5, C	134.4, C	134.6, C
8	110.6, C	108.4, C	112.1, C	111.4, C
9	156.2, C	153.6, C	156.5, C	156.6, C
10	108.0, CH	109.4, CH	107.9, CH	107.8, CH
11	130.7, CH	131.9, CH	130.7, CH	130.8, CH
12	108.0, CH	109.4, CH	107.9, CH	107.8, CH
13	156.2, C	153.6, C	156.5, C	156.6, C
14	21.0, CH ₃	21.3, CH ₃	21.2, CH ₃	21.1, CH ₃
1'	20.4, CH ₂	19.6, CH ₂	133.7, C	30.5, CH ₂
2'	32.4, CH ₂	31.0, CH ₂	129.9, CH	140.9, C
3'	174.3, C	175.1, C	128.5, CH	129.7, CH
4'		52.2, CH₃	127.9, CH	128.9, CH
5′			128.5, CH	126.5, CH
6'			129.9, CH	128.9, CH
7'				129.7 CH

Table 2. ¹³C NMR data of 1-4.

The HMBC correlations from H-1′, to C-1, C-2, C-3, from H-14 to C-5, C-6, C-7, from H-5 to C-3a, C-4, and from H-7 to C-1, C-3a suggested the presence of an indenone fragment (rings A and B) (Figure 2). Additionally, the ¹H-¹H COSY correlations of H-10/H-11/H-12, together with the HMBC correlations from H-12 to C-3, C-8 and C-13, and from H-11 to C-13, completed the 2,6-dihydroxybenzoyl fragment (ring C), which connected to the indenone ring at C-3. The structures of ring A, B and C were further confirmed by comparison of ¹H and ¹³C NMR spectra between 1 and 5 [23]. Furthermore, the ¹H-¹H COSY correlation of H-1′/H-2′ and the HMBC correlations from H-1′, H-2′ to C-3′, from H-1′ to C-1, C-2, C-3, and from H-2′, to C-2 indicated the presence of the 2-carboxyethyl group, which was assigned to be connected to the indenone ring at C-2. Thus, the structure of 1 was deduced, named cytoindenone A.




Figure 2. Key COSY and HMBC correlations of 1-4 and 6-7.

^a Data were recorded in Actone- d_6 at 100 MHz for ¹³C NMR. ^b Data were recorded in CDCl₃ at 100 MHz for ¹³C NMR. ^c Data were recorded in CD₃OD at 150 MHz for ¹³C NMR.

Mar. Drugs **2023**, 21, 181 4 of 10

Compound **2** was isolated as brown oil. Its molecular formula was determined as $C_{20}H_{18}O_6$ (12 degrees of unsaturation) in terms of HREIMS analysis at m/z 377.09985 [M + Na]+ (calcd. for $C_{20}H_{18}O_6Na$, 377.09956). Analysis of the 1H and ^{13}C NMR spectroscopic data of **2** (Tables 1 and 2) revealed mostly similarities with that of **1**, except that the hydroxyl group was substituted with the methoxy group (δ_H 3.58, δ_C 52.2) at C-3′. Combined with the HMBC from H-4′ to C-3′ (Figure 2), the structure of compound **2** was clearly confirmed, named 3′-methoxycytoindenone A.

Compound **3** was acquired as brown oil and had a molecular formula of C₂₂H₁₆O₄, determined by HRESIMS data m/z 367.09424 [M + Na]⁺ (calcd. 367.09408) with 15 degrees of unsaturation. The ¹H NMR spectrum of **3** displayed the signal for ten olefinic protons ($\delta_{\rm H}$ 7.30, 7.30, 7.15, 7.15, 7.13, 6.99, 6.87, 6.63, 6.33 and 6.33) and one methyl ($\delta_{\rm H}$ 2.27). The ¹³C NMR data exhibited one carbonyl ($\delta_{\rm C}$ 199.1), three aromatic rings ($\delta_{\rm C}$ 156.5, 156.5, 153.1, 141.9, 134.4, 133.7, 130.7, 129.9, 129.9, 128.5, 128.5, 127.9, 127.1, 125.1, 116.9, 112.1, 107.9 and 107.9), two olefinic carbons for one double bond ($\delta_{\rm C}$ 154.0, 133.6) and one methyl ($\delta_{\rm C}$ 21.2) (Tables 1 and 2). According to 1D NMR and 2D NMR data, the rings A, B and C of **2** were similar to that of **1**. The obvious difference was the absence of the 2-carboxyethyl group at the C-2 position of compound **1** and the presence of a phenyl group (ring D) at the C-2 position of compound **3**. Meanwhile, the ¹H-¹H COSY correlations of H-3'/H-4'/H-5' failed to be identified because the chemical shifts of H-3', H-4' and H-5' were overlapped; the ¹H-¹H COSY correlations of H-2'/H-3', the HMBC from H-2' to C-2, C-5', and from H-3' to C-1' also indicated that ring D was formed and connected to the indenone ring at C-2, and the structure of compound **3** was determined, named cytoindenone B.

Compound 4 was obtained as brown oil. The molecular formula was determined as C₂₃H₁₈O₄ on the basis of HRESIMS data at m/z 381.10980 [M + Na]⁺ (calcd. for C₂₃H₁₈O₄Na, 381.10973), which was thus determined to possess 15 degrees of unsaturation. The ¹H and ¹³C NMR spectroscopic data were listed in Tables 1 and 2, which suggested that the structure of compound 4 was similar to compound 3, except the presence of methylenes (δ H 3.41, δ C 30.5). Similarly, the ¹H-¹H COSY correlations of H-3'/H-4'/H-5'/H-6'/H-7' failed to be identified because of the overlapping chemical shifts. Combined with the HMBC from H-1' to C-1, C-2, C-3, C-2', C-3', and from H-3', H-4' to C-5' (Figure 2), ring D was formed and C-1' was connected to the indenone ring and ring D at C-2 and C-2', and the structure of compound 5 was clearly confirmed, named cytoindenone C.

Compound 6 was isolated as white powder and assigned an HRESIMS ion peak at m/z 395.11005 ([M + Na]+, calcd. for C₂₀H₂₀O₇Na, 395.11012), which perfectly matched the molecular formula of C₂₀H₂₀O₇ with 11 degrees of unsaturation. The ¹H NMR spectrum of **6** displayed the signal for five olefinic protons (δ H 7.25, 7.18, 6.87, 6.27 and 6.27), one methoxyl (δ H 3.63), three methylenes (δ H 2.96, 2.32 and 1.85) and one methyl (δ H 2.36). The 13 C NMR data revealed 20 carbon resonances, involving two carbonyls (δc 204.1 and 202.2), one ester carbonyl (dc 175.5), two aromatic rings (δc 163.2, 163.2, 155.0, 140.8, 137.8, 137.0, 130.0, 121.6, 121.6, 112.7, 108.1, 108.1), one methoxyl (δc 52.0), three methylenes (δc 38.9, 33.7 and 20.6) and one methyl (δc 21.3) (Table 3). According to 1D NMR and 2D NMR data, the benzophenone moiety of 6 was similar to cytorhizophin C [24]. The only difference between them were that the popionyl group at the C-13 position of cytorhizophin C was replaced by the 5-methoxy-5-oxopentanoyl group of compound 6. The ¹H-¹H COSY correlations of H-16/H-17/H-18, together with the HMBC correlations from H-16 to C-13 and C-15, from H-17 to C-15, and from H-18, H-20 to C-19 indicated that the 5-methoxy-5oxopentanoyl group was located at C-13. Therefore, the structure of 6 was deduced and named cytorhizophin J.

Mar. Drugs 2023, 21, 181 5 of 10

Table 3. 1H and 13C NMR data for 6.

. 6 a			
No.	δc, Type	δн Mult (J in Hz)	
1	108.1, CH	6.27, d (8.2)	
2	137.0, CH	7.18, t (8.2)	
3	108.1, CH	6.27, d (8.2)	
4	163.2, C		
5	112.7, C		
6	163.2, C		
7	204.1, C		
8	130.0, C		
9	155.0, C		
10	121.6, CH	6.87, s	
11	140.8, C		
12	121.6, CH	7.25, s	
13	137.8, C		
14	21.3, CH ₃	2.36, s	
15	202.2, C		
16	38.9, CH ₂	2.96, t (7.5)	
17	20.6, CH ₂	1.85, m	
18	33.7, CH ₂	2.32, t (7.3)	
19	175.5, C		
20	52.0, CH ₃	3.63, s	

^a Data were recorded in CD₃OD at 400 MHz for ¹H NMR and 100 MHz for ¹³C NMR.

Compound 7 was acquired as colorless oil. Its molecular formula C11H12O4 (six degrees of unsaturation) was established on the basis of HREIMS analysis at m/z 209.08093 [M + H]⁺ (calcd. For C₁₁H₁₃O₄, 209.08084). Analysis of the ¹H and ¹³C NMR spectroscopic data of 7 (Table 4) revealed mostly similarities to 3,4-dihydro-4β,6-dihydroxy-5-methoxy- 2α -methyl-1(2H)-naphthalenone [25]. The main difference between them were the absence of one methine at δ_H 2.98 (1H, m, H-2 β) and one methyl at δ_H 1.11 (3H, d, J = 6.8 Hz, 2-Me) in 3,4-dihydro-4 β ,6-dihydroxy-5-methoxy-2 α -methyl-1(2H)-naphthalenone and the presence of one methylene at $\delta_{\rm H}$ 2.99 (1H, m, H_a-2) and 2.43 (1H, dt, J = 17.2, 3.6, H_b-2) in 7, which was confirmed by the ¹H-¹H COSY correlations of H_a, b-2/H_a, b-3/H-4, and the HMBC correlations (Figure 2) from Ha, b-2 to C-1, C-8a. Thus, compound 7 was assigned as shown in Figure 1, and named 4,6-dihydroxy-5-methoxy- α -tetralone. However, chiral HPLC analysis of 7 showed two peaks (t_R 21.3 min and 24.6 min), and subsequent chiral HPLC purification of (\pm)-7 led to the separation of the two enantiomers (+)-7 and (–)-7. The absolute configurations of (+)-7 and (–)-7 were determined as 4S and 4R by the comparison of the observed specific rotation value [(+)-7: $[\alpha]_D^{25}$ + 31.3, (+)-7: $[\alpha]_D^{25}$ – 31.5)] of compounds (±)-7 with those for (4*S*)-4,8-dihydroxy- α -tetralone ($[\alpha]_D^{27}$ + 24.5), (4*S*)-5-hydroxy-4-methoxy-α-tetralone ($[\alpha]_D^{27}$ + 50.0), (4*R*)-4,8-dihydroxy-α-tetralone ($[\alpha]_D^{27}$ – 26.0) and (4*R*)- 5-hydroxy-4-methoxy-α-tetralone ($[\alpha]_D^{27}$ – 50.0) (Figure S39) [26].

Table 4. ¹H and ¹³C NMR data for 7.

7ª			
No.	δc, Type	δ н Mult (J in Hz)	
1	199.6, C		
2	33.0, CH ₂	2.99, m	
		2.43, dt (17.2, 3.6)	
3	31.6, CH ₂	2.26, m	
		2.17, m	

Mar. Drugs **2023**, 21, 181 6 of 10

4	61.7, CH	5.26, t (3.1)
4a	139.9, C	
5	146.2, C	
6	157.5, C	
7	117.8, C	6.92, d (8.6)
8	125.4, CH	7.67, d (8.6)
8a	125.6, C	
9	61.9, CH₃	

^a Data were recorded in CD₃OD at 400 MHz for ¹H NMR and 100 MHz for ¹³C NMR.

2.2. Biological Evaluation

Compounds 1–7 were tested for their DPPH· scavenging activity. As seen in Table 5, the results indicated that compounds 1, 4–6 showed significant DPPH· scavenging activities with EC50 values ranging from 9.5 to 16.6 μ M, better than the positive control ascorbic acid (21.9 μ M) [27,28]; compounds 2–3 also exhibited DPPH· scavenging activities comparable to ascorbic acid.

The antioxidant activities of phenolic compounds were widely investigated and the phenolic content and the side chain functional groups had significant influences on DPPH-scavenging activities [29,30]. Comparing the activities of compounds 1–2, when the carboxyl group at C-3′ was esterified by the methyl group, the antioxidant activity of 2 decreases significantly. Comparing the activities of compounds 2–5, the higher activity of compound 5 was due to the accessibility of the phenolic OH group by DPPH-. The activities of compounds 2–4 were due to the presence of bulky groups at C-2 obstructing DPPH-access to the phenolic OH group. Compound 6 could be regarded as a precursor of compound 2, which formed ring B through C7–C16 aldol-type cyclization. Compound 6 exhibited the strongest antioxidant activity due to the disconnection of ring B and the smallest steric hindrance of phenolic ring C. Compounds (+)-7 and (–)-7 showed no antioxidant activities due to the reduction of the phenolic content.

	Table 5. DPPH-	scavenging	activities	of com	pounds 1-9.
--	----------------	------------	------------	--------	-------------

Compound	% Inhibition (100 μM)	EC50 (μM)
1	90.8	11.5 ± 0.1
2	72.5	21.5 ± 1.0
3	69.0	19.7 ± 1.8
4	78.2	16.6 ± 0.4
5	81.0	12.4 ± 0.5
6	87.3	9.5 ± 0.1
(+)-7	12.0	-
(-)-7	4.2	_
ascorbic acid ^a	91.4	21.9 ± 0.3

^a positive control.

3. Experimental Section

3.1. General Experimental Procedures

Optical rotations were performed on an MCP300 (Anton Paar, Shanghai, China). UV data were measured on a Shimadzu UV-2600 spectrophotometer (Shimadzu, Kyoto, Japan). The ECD experiment data were conducted with a J-810 spectropolarimeter (JASCO, Tokyo, Japan). IR spectra were measured on an IR Affinity-1 spectrometer (Shimadzu, Kyoto, Japan). Melting points were recorded on a Fisher-Johns hot-stage apparatus. The NMR spectra were tested on a Bruker Avance spectrometer (Bruker, Beijing, China) (Compounds 3–4: 600 MHz for ¹H and 150 MHz for ¹³C; compounds 1–2 and 5–7: 400 MHz for ¹H and 100 MHz for ¹³C, respectively). HRESIMS data were conducted on a ThermoFisher LTQ-Orbitrap-LC-MS spectrometer (Palo Alto, CA, USA). Column chromatography (CC) was performed on silica gel (200–300 mesh, Marine Chemical Factory, Qingdao, China)

Mar. Drugs **2023**, 21, 181 7 of 10

and Sephadex LH-20 (Amersham Pharmacia, Piscataway, NJ, USA). Semi-preparative HPLC (Ultimate 3000 BioRS, Thermo Scientific, Germany) were conducted using the Chiral INA column (5 μ m, 4.6 × 250 mm, Phenomenex, Piscataway, NJ, USA), and the Chiral-cel ODH column (5 μ m, 4.6 × 250 mm, Daicel, Tokyo, Japan) for chiral separation.

3.2. Fungal Material

The fungal strain NSHSJ-2 used in this study was isolated from the fresh stem of mangrove plant *Sonneratia caseolaris*, which was collected in June 2020 from the Nansha Mangrove National Nature Reserve in Guangdong Province, China. The strain was identified as *Cytospora heveae* (compared to no. OQ423127) upon the analysis of ITS sequence data of the rDNA gene. The ITS sequence data obtained from the fungal strain has been submitted to GenBank with accession no. OL780505.1. A voucher strain was deposited in our laboratory.

3.3. Fermentation, Extraction and Isolation

The fungus Cytospora heveae NSHSJ-2 was fermented on solid cultured medium (sixty 1000 mL Erlenmeyer flasks, each containing 50 g of rice and 50 mL of distilled water with 3% sea salt) for 30 days at 25 °C. The cultures were extracted three times with MeOH to yield 22.9 g of residue. Then, the crude extract was eluted by using a gradient elution with petroleum ether/EtOAc from 9:1 to 0:10 (*v*/*v*) on silica gel CC to get six fractions (Fr. A–F). Fr. D (297 mg) was subjected to silica gel CC (CH₂Cl₂/MeOH, v/v, 800:1 to 200:1) to obtain three subfractions (Fr. D₁–D₃). Fr. D₂ (9.4 mg) was separated by normal phase HPLC on a chiral column (INA), using hexane/isopropanol (80:20, v/v, flow rate: 1.0 mL/min) as the solvent system, to yield compounds 3 (1.6 mg, t_R 14.0 min) and 4 (4.3 mg, t_R 21.2 min). Fr. D₃ (83.4 mg) was applied to Sephadex LH-20 CC (CH₂Cl₂/MeOH, v/v, 1:1) to yield compound 5 (26 mg). Fr. E (749 mg) was subjected to silica gel CC (CH₂Cl₂/MeOH, v/v, 100:1 to 20:1) to afford four fractions (Fr. E₁-E₄). Fr. E₂ (204 mg) was subjected to silica gel CC (petroleum ether/EtOAc, v/v, 7:3) to yield compounds 2 (46.5 mg). Fr. E₃ (56.4 mg) was subjected to silica gel CC (petroleum ether/EtOAc, v/v, 6:4) to yield compounds 6 (15.4) mg) and (±)-7 (9.4 mg). The chiral HPLC separation of (±)-7 was accomplished over a chiral column (ODH) (column size: 4.6 × 250 mm, 5 µm; flow rate: 1.0 mL/min; solvent: n-hexaneisopropanol = 90:10) to yield (+)-7 (1.4 mg, t_R 21.3 min) and (-)-7 (7.3 mg, t_R 24.6 min). Fr. E4 (103 mg) was purified by Sephadex LH-20 CC and eluted with MeOH to obtain compound 1 (27.9 mg).

Cytoindenone A (1): brown oil; UV (MeOH) λ_{max} (log ε): 205 (1.24), 247 (0.53) nm; IR ν_{max} 3282, 2949, 2835, 1695, 1435, 1276, 1010, 781 cm⁻¹; HRESIMS m/z 363.08383 [M + Na] ⁺ (calcd. for C₁₉H₁₆O₆Na, 363.08391); ¹H NMR (400 MHz, Actone- d_6) data and ¹³C NMR (100 MHz, Actone- d_6) data (see Tables 1 and 2).

3'-methoxycytoindenone A (2): brown oil; UV (MeOH) λ_{max} (log ε): 204 (0.90), 248 (0.42) nm; IR ν_{max} 3360, 2954, 2920, 1697, 1622, 1462, 1278, 1012, 783 cm⁻¹; HRESIMS m/z 377.09985 [M + Na] + (calcd. for C₂₀H₁₈O₆Na, 377.09956); ¹H NMR (400 MHz, CDCl₃) data and ¹³C NMR (100 MHz, CDCl₃) data (see Tables 1 and 2).

Cytoindenone B (3): brown oil; UV (MeOH) λ_{max} (log ε): 203 (0.32), 272 (0.15) nm; IR ν_{max} 3365, 2949, 2850, 1689, 1618, 1462, 1280, 1014, 792 cm⁻¹; HRESIMS m/z 367.09424 [M + Na] + (calcd. for C₂₂H₁₆O₄Na, 367.09408); ¹H NMR (600 MHz, CD₃OD) data and ¹³C NMR (150 MHz, CD₃OD) data (see Tables 1 and 2).

Cytoindenone C (4): brown oil; UV (MeOH) λ_{max} (log ε): 205 (0.80), 249 (0.35) nm; IR ν_{max} 3358, 2922, 2852, 1683, 1618, 1462, 1276, 1012, 700 cm⁻¹; HRESIMS m/z 381.10980 [M + Na] + (calcd. for C₂₃H₁₈O₄Na, 381.10973); ¹H NMR (600 MHz, CD₃OD) data and ¹³C NMR (150 MHz, CD₃OD) data (see Tables 1 and 2).

Cytorhizophin J (6): white powder, mp 190.2–191.6 °C; UV (MeOH) λ_{max} (log ε): 216 (1.43), 270 (0.67) nm; IR ν_{max} 3342, 2924, 1716, 1627, 1456, 1338, 1226, 1031, 925, cm⁻¹; HRESIMS m/z 395.11005 [M + Na] + (calcd. for C₂₀H₂₀O₇Na, 395.11012); ¹H NMR (400 MHz, CD₃OD) and ¹³C NMR (100 MHz, CD₃OD) data (see Table 3).

Mar. Drugs **2023**, 21, 181 8 of 10

(±)-4,6-dihydroxy-5-methoxy-α-tetralone (7): colorless oil; UV (MeOH) λ_{max} (log ε): 205 (1.63), 230 (1.29), 282 (1.01) nm; IR ν_{max} 3261, 2943, 2839, 1660, 1578, 1305, 1290, 1190, 1012 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) data and ¹³C NMR (100 MHz, CD₃OD) data (see Table 4); HRESIMS m/z 209.08093 [M + H] + (calcd for C₁₁H₁₃O₄, 209.08084). (+)-7, [α]_D²⁵+ 31.3 (c 0.1 MeOH); ECD (c = 0.18 mg/mL, MeOH) λ_{max} ($\Delta\varepsilon$) 205 (+13.5), 230 (+8.4), 284 (+7.0), 327 (-6.0). (-)-7, [α]_D²⁵- 31.5 (c 0.1 MeOH); ECD (c = 0.17 mg/mL, MeOH) λ_{max} ($\Delta\varepsilon$) 205 (-14.9), 225 (-6.1), 277 (-5.4), 320 (+5.8).

3.4. Biological Assays

The DPPH·radical scavenging activities of compounds 1–7 were determined according to the reported method [14,28]. The DPPH· radical scavenging test was performed in 96-well microplates. Testing materials (compounds 1–7) were added to 100 μ L (0.16 mmol/L) DPPH solution in MeOH at a range of 100 μ L solutions of different concentrations (6.25–100 μ M). Ascorbic acid was prepared as positive control at the same concentrations (Table 5). Absorbance was recorded at λ = 517 nm after 45 min of incubation in the dark. The DPPH·radical scavenging activity was calculated using the formula:

DPPH radical scavenging activity (%) = [(Abscontrol – Abssample)/Abscontrol] × 100

4. Conclusions

In summary, seven new polyketides including four indenone derivatives, cytoin-denones A–C (1, 3–4), 3′-methoxycytoindenone A (2), a new benzophenone derivative, cytorhizophin J (6) and a pair of undescribed tetralone enantiomers, (\pm)-4,6-dihydroxy-5-methoxy-1-tetralone (7), together with a known compound (5), were isolated from the endophytic fungus *Cytospora heveae* NSHSJ-2. Compound 3 represented the first natural indenone monomer substituted by two benzene moieties at C-2 and C-3. Their structures were confirmed by the analysis of NMR, HR-MS and ECD spectra. All of the compounds were tested for their antioxidative activities. Compounds 1, 4–6 showed potent DPPH-scavenging activities with EC50 values ranging from 9.5 to 16.6 μ M, better than the positive control ascorbic acid (21.9 μ M); compounds 2–3 also exhibited DPPH-scavenging activities comparable to ascorbic acid.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/md21030181/s1: Figure S1. HRESIMS spectrum of compound 1; Figure S2. 1H NMR spectrum of compound 1 (400 MHz, Actone-d₆); Figure S3. ¹³C NMR spectrum of compound 1 (100 MHz, Actone-d₆); Figure S4. ¹H-¹H COSY spectrum of compound 1; Figure S5. HSQC spectrum of compound 1; Figure S6. HMBC spectrum of compound 1; Figure S7. HRESIMS spectrum of compound 2; Figure S8. ¹H NMR spectrum of compound 2 (400 MHz, CDCl₃); Figure S9. ¹³C NMR spectrum of compound 2 (100 MHz, CDCl₃); Figure S10. ¹H-¹H COSY spectrum of compound 2; Figure S11. HSQC spectrum of compound 2; Figure S12. HMBC spectrum of compound 2; Figure S13. HRESIMS spectrum of compound 3; Figure S14. 1 H NMR spectrum of compound 3 (600 MHz, CD $_3$ OD); Figure S15. 13C NMR spectrum of compound 3 (150 MHz, CD3OD); Figure S16. 1H-1H COSY spectrum of compound 3; Figure S17. HSQC spectrum of compound 3; Figure S18. HMBC spectrum of compound 3; Figure S19. HRESIMS spectrum of compound 4; Figure S20. 1H NMR spectrum of compound 4 (600 MHz, CD₃OD); Figure S21. ¹³C NMR spectrum of compound 4 (150 MHz, CD₃OD); Figure S22. ¹H-¹H COSY spectrum of compound 4; Figure S23. HSQC spectrum of compound 4; Figure S24. HMBC spectrum of compound 4; Figure S25. HRESIMS spectrum of compound 6; Figure S26. ¹H NMR spectrum of compound 6 (400 MHz, CD₃OD); Figure S27. ¹³C NMR spectrum of compound 6 (100 MHz, CD3OD); Figure S28. 1H-1H COSY spectrum of compound 6; Figure S29. HSQC spectrum of compound 6; Figure S30. HMBC spectrum of compound 6; Figure S31. HRESIMS spectrum of compound 7; Figure S32. ¹H NMR spectrum of compound 7 (400 MHz, CD₃OD); Figure S33. ¹³C NMR spectrum of compound 7 (100 MHz, CD₃OD); Figure S34. ¹H-¹H COSY spectrum of compound 7; Figure S35. HSQC spectrum of compound 7; Figure S36. HMBC spectrum of compound 7; Figure S37. ECD spectrum of compound (+)-7; Figure S38. ECD spectrum of compound (-)-7; Figure S39. Structure of compounds 3,4-dihydro- 4β ,6-dihydroxy-5-methoxy- 2α -methyl-1(2H)-naphthalenone, (4S)-4,8-dihydroxy- α -tetralone, (4R)-4,8-dihydroxy- α -tetralone, (4S)-5-hydroxy-4-methoxy- α -tetralone and (4*R*)- 5-hydroxy-4-methoxy- α -tetralone.

Mar. Drugs **2023**, 21, 181 9 of 10

Author Contributions: G.Z. performed the experiments and wrote the paper; T.L., W.Y. and B.S. participated in the experiments; Y.C., B.W. and Y.O. analyzed the data and discussed the results; H.Y. and Z.S. reviewed the manuscript; Z.S. designed and supervised the experiments. All authors have read and agreed to the published version of the manuscript.

Funding: We thank the National Natural Science Foundation of China (U20A2001, 42276114, 82104228), the Key-Area Research and Development Program of Guangdong Province (2020B1111030005), and the GDAS Special Project of Science and Technology Development (Grant No. 2021GDASYL–20210103057) for the generous support.

Data Availability Statement: Data are contained within the article and Supplementary Material.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Prasher, P.; Sharma, M. Medicinal chemistry of indane and its analogues: A mini review. *ChemistrySelect* **2021**, *6*, 2658–2677.
- 2. Nigam, R.; Babu, K.R.; Ghosh, T.; Kumari, B.; Akula, D.; Rath, S.N.; Das, P.; Anindya, R.; Khan, F.A. Indenone derivatives as inhibitor of human DNA dealkylation repair enzyme AlkBH3. *Bioorgan. Med. Chem.* **2018**, *26*, 4100–4112.
- 3. Hao, X.D.; Chang, J.; Qin, B.Y.; Zhong, C.; Chu, Z.B.; Huang, J.; Zhou, W.J.; Sun, X. Synthesis, estrogenic activity, and anti-osteoporosis effects in ovariectomized rats of resveratrol oligomer derivatives. *Eur. J. Med. Chem.* **2015**, 102, 26–38.
- Ahn, J.H.; Shin, M.S.; Jung, S.H.; Kang, S.K.; Kim, K.R.; Rhee, S.D.; Jung, W.H.; Yang, S.D.; Kim, S.J.; Woo, J.R.; et al. Indenone Derivatives: A Novel Template for Peroxisome Proliferator-Activated Receptor γ (PPARγ) Agonists. J. Med. Chem. 2006, 49, 4781–4784.
- 5. Liu, J.; Liu, L.; Zheng, L.; Feng, K.W.; Wang, H.T.; Xu, J.P.; Zhou, Z.Z. Discovery of novel 2,3-dihydro-1*H*-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease. *Eur. J. Med. Chem.* **2022**, 238, 114503.
- Ernst-Russell, M.A.; Chai, C.L.L.; Wardlaw, J.H.; Elix, J.A. Euplectin and Coneuplectin, New Naphthopyrones from the Lichen Flavoparmelia euplecta. J. Nat. Prod. 2000, 63, 129–131.
- Li, X.L.; Ru, T.; Navarro-Vázquez, A.; Lindemann, P.; Nazaré, M.; Li, X.W.; Guo, Y.W.; Sun, H. Weizhouochrones: Gorgonian-Derived Symmetric Dimers and Their Structure Elucidation Using Anisotropic NMR Combined with DP4+ Probability and CASE-3D. J. Nat. Prod. 2022, 85, 1730–1737.
- 8. Du, Y.E.; Byun, W.S.; Lee, S.B.; Hwang, S.; Shin, Y.H.; Shin, B.; Jang, Y.J.; Hong, S.; Shin, J.; Lee, S.K.; et al. Formicins, *N*-Acetyl-cysteamine-Bearing Indenone Thioesters from a Wood Ant-Associated Bacterium. *Org. Lett.* **2020**, 22, 5337–5341.
- 9. Luo, H.F.; Zhang, L.P.; Hu, C.Q. Five novel oligostilbenes from the roots of Caragana sinica. Tetrahedron 2001, 57, 4849–4854.
- 10. Sema, D.K.; Lannang, A.M.; Tatsimo, S.J.N.; Rehman, M.; Yousuf, S.; Zoufou, D.; Iqbal, U.; Wansi, J.D.; Sewald, N.; Choudhary, M.I. New indane and naphthalene derivatives from the rhizomes of *Kniphofia reflexa* Hutchinson ex Codd. *Phytochem. Lett.* **2018**, 26, 78–82.
- 11. Jaki, B.; Heilmann, J.; Sticher, O. New Antibacterial Metabolites from the Cyanobacterium *Nostoc commune* (EAWAG 122b). *J. Nat. Prod.* **2000**, *63*, 1283–1285.
- 12. Kim, H.; Yang, I.; Ryu, S.Y.; Won, D.H.; Giri, A.G.; Wang, W.H.; Choi, H.; Chin, J.; Hahn, D.; Kim, E.; et al. Acredinones A and B, Voltage-Dependent Potassium Channel Inhibitors from the Sponge-Derived Fungus *Acremonium* sp. F9A015. *J. Nat. Prod.* **2015**, *78*, 363–367.
- 13. Liu, Z.M.; Qiu, P.; Li, J.; Chen, G.Y.; Chen, Y.; Liu, H.J.; She, Z.G. Anti-inflammatory polyketides from the mangrove-derived fungus *Ascomycota* sp. SK2YWS-L. *Tetrahedron* **2018**, 74, 746–751.
- 14. Tan, C.B.; Liu, Z.M.; Chen, S.H.; Huang, X.S.; Cui, H.; Long, Y.H.; Lu, Y.J.; She, Z.G. Antioxidative Polyketones from the Mangrove-Derived Fungus *Ascomycota* sp. SK2YWS-L. *Sci. Rep.* **2016**, *6*, 36609.
- 15. Zhong, C.; Liu, X.H.; Chang, J.; Yu, J.M.; Sun, X. Inhibitory effect of resveratrol dimerized derivatives on nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. *Bioorg. Med. Chem. Lett.* **2013**, 23, 4413–4418.
- 16. Chen, S.H.; Cai, R.L.; Liu, Z.M.; Cui, H.; She, Z.G. Secondary metabolites from mangrove-associated fungi: Source, chemistry and bioactivities. *Nat. Prod. Rep.* **2022**, *39*, 560–595.
- 17. Xu, J. Bioactive natural products derived from mangrove-associated microbes. RSC Adv. 2015, 5, 841–892.
- 18. Tan, Q.; Yang, W.C.; Zhu, G.; Chen, T.; Wu, J.; Zhu, Y.J.; Wang, B.; Yuan, J.; She, Z.G. A Pair of Chromone Epimers and an Acetophenone Glucoside from the Mangrove Endophytic Fungus *Mycosphaerella* sp. L3A1. *Chem. Biodivers.* **2022**, *19*, e202200998.
- 19. Chen, T.; Yang, W.C.; Li, T.B.; Yin, Y.H.; Liu, Y.F.; Wang, B.; She, Z.G. Hemiacetalmeroterpenoids A–C and Astellolide Q with Antimicrobial Activity from the Marine-Derived Fungus *Penicillium* sp. N-5. *Mar. Drugs* **2022**, *20*, 514.
- Chen, Y.; Yang, W.C.; Zou, G.; Wang, G.S.; Kang, W.Y.; Yuan, J.; She, Z.G. Cytotoxic Bromine- and Iodine-Containing Cytochalasins Produced by the Mangrove Endophytic Fungus *Phomopsis* sp. QYM-13 Using the OSMAC Approach. *J. Nat. Prod.* 2022, 85, 1229–1238.
- 21. Zang, Z.M.; Yang, W.C.; Cui, H.; Cai, R.L.; Li, C.Y.; Zou, G.; Wang, B.; She, Z.G. Two Antimicrobial Heterodimeric Tetrahydroxanthones with a 7,7'-Linkage from Mangrove Endophytic Fungus *Aspergillus flavus* QQYZ. *Molecules* **2022**, 27, 2691.

Mar. Drugs **2023**, 21, 181

22. Jiang, H.M.; Cai, R.L.; Zang, Z.M.; Yang, W.C.; Wang, B.; Zhu, G.; Yuan, J.; She, Z.G. Azaphilone derivatives with anti-inflammatory activity from the mangrove endophytic fungus *Penicillium sclerotiorum* ZJHJJ-18. *Bioorg. Chem.* **2022**, 122, 105721.

- 23. Liu, H.X.; Liu, Z.M.; Chen, Y.C.; Tan, H.B.; Zhang, W.G.; Zhang, W.M. Polyketones from the endophytic fungus *Cytospora rhi-zophorae*. *Nat. Prod. Res.* **2021**, *37*, 1053–1059. https://doi.org/10.1080/14786419.2021.1998898.
- 24. Liu, H.X.; Tan, H.B.; Wang, W.X.; Zhang, W.G.; Chen, Y.C.; Liu, S.N.; Liu, Z.M.; Li, H.H.; Zhang, W.M. Cytorhizophins A and B, benzophenone-hemiterpene adducts from the endophytic fungus *Cytospora rhizophorae*†. *Org. Chem. Front.* **2019**, *6*, 591–596.
- 25. Auamcharoen, W.; Kijjoa, A.; Chandrapatya, A.; Pinto, M.M.; Silva, A.M.S.; Naengchomnong, W.; Herz, W. A new tetralone from *Diospyros cauliflora*. *Biochem. Syst. Ecol.* **2009**, *37*, 690–692.
- 26. Machida, K.; Matsuoka, E.; Kasahara, T.; Kikuchi, M. Studies on the Constituents of *Juglans* Species. I. Structural Determination of (4S)- and (4R)-4-Hydroxy-α-tetralone Derivatives from the Fruit of *Juglans mandshurica* MAXIM. var. *sieboldiana* Makino. *Chem. Pharm. Bull.* **2005**, *53*, 934–937.
- 27. Chen, Y.; Yang, W.C.; Zou, G.; Chen, S.Y.; Pang, J.Y.; She, Z.G. Bioactive polyketides from the mangrove endophytic fungi Phoma sp. SYSUSK-7. *Fitoterapia* **2019**, *139*, 10436.
- 28. Qiu, P.; Liu, Z.M.; Chen, Y.; Cai, R.L.; Chen, G.Y.; She, Z.G. Secondary Metabolites with *α*-Glucosidase Inhibitory Activity from the Mangrove Fungus *Mycosphaerella* sp. SYSU-DZG01. *Mar. Drugs* **2019**, *17*, 483.
- 29. Ichikawa, K.; Sasada, R.; Chiba, K.; Gotoh, H. Effect of Side Chain Functional Groups on the DPPH Radical Scavenging Activity of Bisabolane-Type Phenols. *Antioxidants* **2019**, *8*, 65.
- 30. Odame, F.; Hosten, E.C.; Betz, R.; Krause, J.; Frost, C.L.; Lobb, K.; Tshentu, Z.R. Synthesis, characterization, computational studies and DPPH scavenging activity of some triazatetracyclic derivatives. *J. Iran. Chem. Soc.* **2021**, *18*, 1979–1995.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.